



CHEMCON
Speciality Chemicals Limited



CIN : U24231GJ1988PLC011652

August 10, 2021

To,
BSE Limited
Listing Compliance & Legal Regulatory
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 023

To,
National Stock Exchange of India Limited
Listing & Compliance
Exchange Plaza, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051

Stock Code: **543233**

Stock Symbol: **CHEMCON**

Dear Sir/Madam,

Sub: Press Release - Unaudited Financial Results for the quarter ended June 30, 2021.

Please find enclosed a copy of the press release with regards to the Unaudited Financial Results of the Company for the quarter ended June 30, 2021.

A copy of the same will also be uploaded on the company's website www.cscpl.com.

This is for your information and records.

Thanking you,
Yours faithfully,

For Chemcon Speciality Chemicals Limited


Shahilkumar Kapatel
Company Secretary & Compliance Officer
Membership No.: A52211




- Revenue Stood at Rs 57.2 Cr, growth of 25% on YoY basis
- EBITDA at Rs 17.9 Cr, growth of 28% on YoY basis
- PAT at Rs 13.4 Cr, growth of 52% on YoY basis

Vadodara, August 10th, 2021: Chemcon Speciality Chemicals Limited, a leading manufacturer of specialized chemicals, such as Hexamethyldisilazane (“HMDS”), Chloromethyl Isopropyl Carbonate (“CMIC”) and inorganic bromides, announced its un-audited financial results for the quarter ended on June 30th 2021.


Financial and Operational Highlights



Total Volume (MTPA)



Production Volume (MTPA)



Commenting on the results, Mr. Kamal Aggarwal, Chairman & MD said, *“The new financial year has been presented with a new set of challenges led by second wave. We have seen mixed reactions from our clients. It did not dent our pharma chemicals business as compared to last year, but it certainly halted the business momentum of bromides which was heading towards normalcy. Due to slower capex by end clients, bromide business has been lower than our expectations. However, we have seen good recovery in Q2FY22.*

We have clocked a total operating revenue of Rs 57.2 cr for the quarter, a growth of 25% on YoY basis and profits after tax of Rs.13.4 cr, a growth of 52% on YoY basis. CMIC business was operating at a healthy level. Our new product 4 CBC has contributed marginally to our revenue. Whereas products like 2,5 DHT and high purity HMDS are likely to gain some traction in coming quarters.

In Q1FY22, HMDS business was impacted due to maintenance work at P7 Unit where we are doing backward integration with our P8 Unit for our key raw material Trimethylchlorosilane (TMCS). Handling these chemicals requires a high degree of technical skill & expertise and therefore the production will be lower in Q2FY22 due to integration process, inspection, and trial run. We expect HMDS business to operate at optimum level from Q3FY22 onwards.

Our P8 & P9 units are likely to commence production in Q3FY22 due to late delivery of materials & equipment. This expansion will increase our capacities & strengthen our product portfolio of pharma chemicals. This is in line with our long-term vision to capture new business opportunities under the Make in India scheme.”

About Chemcon Speciality Chemicals Ltd.

Incorporated in 1988, we are a manufacturer of specialized chemicals, such as HMDS & CMIC which are predominantly used in the pharmaceuticals industry and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry. In terms of production in the CY2019, we were the only manufacturer of HMDS in India and were the third largest manufacturer of HMDS worldwide. We were the largest manufacturer of CMIC in India and the second largest manufacturer of CMIC worldwide. Further, we were the only manufacturer of Zinc Bromide and the largest manufacturer of Calcium Bromide in India. We have 7 manufacturing facilities located at Manjusar near Vadodara in Gujarat. Our business presences are spread in USA, Germany, Italy, S. Korea, China, Japan, UAE, Serbia, Russia, Spain, Thailand and Malaysia. We are a ISO 9001:2015 and ISO 14001:2015 certified company for the “Manufacture and supply of pharmaceutical intermediates, silanes and oilfield chemicals”.

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :



Chemcon Speciality Chemicals Ltd.

CIN - U24231GJ1988PLC011652

Mr. Rajesh Gandhi

Whole-time Director & CFO

Email ID: rajesh@cscpl.com

www.cscpl.com

Investor Relations Advisors :

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Pankti

Majithia

shrikant.sangani@sgapl.net /

pankti.majithia@sgapl.net

+91 9619595686 /+ 91 9619611096

www.sgapl.net